Maximus, Inc.: Form 10-Q for the period ended Dec 31, 2024
Filed with the SEC on Feb 6, 2025 and accepted by EDGAR at Feb 6, 2025, 15:27 ET.
Management's discussion and analysis
As filed, 34,388 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following discussion is intended to help the reader understand our business, financial condition, results of operations, liquidity and capital resources. You should read this discussion in conjunction with "Risk Factors," "Special Note Regarding Forward-Looking Statements," and our financial statements and related notes included in our Annual Report on Form 10-K for fiscal year 2024 filed with the SEC on November 21, 2024 (the "2024 Form 10-K") and elsewhere in this Quarterly Report on Form 10-Q, as applicable.
Business Overview
Maximus, under its mission of Moving People Forward, helps millions of people access the vital government services they need. With nearly 50 years of experience working with local, state, federal, and international government clients, we proudly design, develop, and deliver innovative and impactful programs that change lives. We are driven to strengthen communities and improve the lives of those we serve.
We create value for our customers through our ability to translate health and human services public policy into operating models that achieve outcomes for governments at scale. Our work covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. These services benefit from a market with increasing demographic demand, constrained government budgets, and an increased focus on technology as governments prioritize modernization. We also demonstrate the ability to move quickly, ranging from digitally enabled contact center support services for natural disaster response to swift establishments of public health and safety initiatives, examples of which occurred during the COVID-19 pandemic. Our organic growth has occurred through increased contract scope and entry into new markets. In addition, we have made strategic acquisitions, intended to drive additional organic growth through new capabilities or customer sets gained.
We are progressing through our strategic plan introduced in fiscal year 2022. We believe in further expansion of our business and remain in a strong position to capitalize on organic growth opportunities in our core business. Our strategic plan consists of three central pillars:
- Customer Services, Digitally Enabled. Elevate the customer experience to achieve higher levels of satisfaction, performance, and outcomes through intelligent automation and cognitive computing. The launch of Maximus Total Experience Management (TXM) is evidence of this focus and commitment. TXM is an integrated solution designed to help federal agencies deliver trusted information and government services simply, consistently, and securely. This new differentiated solution seamlessly integrates people, experience, data insights, and secure technologies into one digitally powered platform to reimagine government service delivery.
- Future of Health. Help governments reach the rising demand for health services by growing our clinical capabilities and increasing the level of sophistication of underlying tools to improve the health of people and their communities.
- Advanced Technologies for Modernization. Further our credibility as a technology leader, enabling the transformation of government programs and legacy system environments to be resilient, dynamic, integrated, and equitable.
Our strategic plan is aligned with specific opportunities within all three segments and include a common focus on optimizing processes and simplifying our structure under our Maximus Forward corporate initiative. We also continue to focus on our people - the foundation of our strategy. As an employer of choice, our goal is to continue to prioritize attracting, retaining, developing, and empowering employees as a central part of our plan for achieving future growth.
Financial Overview
A number of factors have affected our results for the first quarter of fiscal year 2025. More detail on these changes is presented below within our "Results of Operations" section.
Results of Operations
The following table sets forth items from our consolidated statements of operations for the three months ended December 31, 2024, and December 31, 2023.
Table MD&A 1: Consolidated Results of Operations
(dollars in thousands, except per share data)
| For the Three Months Ended December 31, 2024 | December 31, 2023 | |
|---|---|---|
| Revenue | $1,402,675 | $1,327,041 |
| Cost of revenue | 1,101,118 | 1,026,987 |
| Gross profit | 301,557 | 300,054 |
| Gross profit percentage | 21.5% | 22.6% |
| Selling, general, and administrative expenses | 191,735 | 169,195 |
| Selling, general, and administrative expenses as a percentage of revenue | 13.7% | 12.7% |
| Amortization of intangible assets | 23,035 | 23,349 |
| Operating income | 86,787 | 107,510 |
| Operating margin | 6.2% | 8.1% |
| Interest expense | 17,522 | 21,507 |
| Other expense, net | 312 | 488 |
| Income before income taxes | 68,953 | 85,515 |
| Provision for income taxes | 27,757 | 21,367 |
| Effective tax rate | 40.3% | 25.0% |
| Net income | $41,196 | $64,148 |
| Earnings per share: | ||
| Basic | $0.69 | $1.05 |
| Diluted | $0.69 | $1.04 |
Our business segments have different factors driving revenue fluctuations and profitability. The sections that follow cover these segments in greater detail. Our revenue reflects fees earned for services provided. Cost of revenue consists of direct costs related to labor and related overhead, subcontractor labor, outside vendors, rent, and other direct costs. The largest component of cost of revenue, approximately two-thirds, is labor, including subcontracted labor.
Table MD&A 2: Changes in Revenue, Cost of Revenue, and Gross Profit for the Three Months Ended December 31, 2024
(dollars in thousands)
| Revenue Dollars | % Change | Cost of Revenue Dollars | % Change | Gross Profit Dollars | % Change | |
|---|---|---|---|---|---|---|
| Three months ended December 31, 2023 | $1,327,041 | $1,026,987 | $300,054 | |||
| Organic effect | 83,088 | 6.3% | 82,156 | 8.0% | 932 | 0.3% |
| Disposal of businesses | (10,896) | (0.8)% | (10,866) | (1.1)% | (30) | —% |
| Currency effect compared to the prior period | 3,442 | 0.3% | 2,841 | 0.3% | 601 | 0.2% |
| Three months ended December 31, 2024 | $1,402,675 | 5.7% | $1,101,118 | 7.2% | $301,557 | 0.5% |
22
Selling, general, and administrative ("SG&A") expenses
Selling, general, and administrative expenses ("SG&A") consist of indirect costs related to general management, marketing, and administration. It is primarily composed of labor costs. These costs may be incurred at a segment level, for dedicated resources that are not client-facing, or at a corporate level. Corporate costs are allocated to segments on a consistent and rational basis. Fluctuations in our SG&A are primarily driven by changes in our administrative cost base, which are not directly driven by changes in our revenue. As part of our work for the U.S. federal government and many states, we allocate these costs using a methodology driven by the U.S. Federal Cost Accounting Standards.
Our SG&A expense for the three months ended December 31, 2024, includes $38.3 million of divestiture-related charges from our sale of businesses in the Outside the U.S. Segment. These charges included accumulated foreign currency losses incurred over two decades of operations, as well as the cost of an indemnification provided to the buyer.
Amortization of intangible assets
Amortization of intangible assets remained consistent for the three months ended December 31, 2024, as compared to three months ended December 31, 2023.
Our balance sheet includes $455 million of intangible assets from a 2021 acquisition. These assets, comprised of customer relationships, technology, and a medical provider network, continue to support medical disability examinations (MDE) contracts with the VA. The greater part of these assets are being amortized over the remaining nine years. In the event that our expectations change with respect to these acquired contracts, the value of these assets and the estimated remaining lives of these assets may need to be adjusted.
Interest Expense
Our interest expense has declined in fiscal year 2025 compared to fiscal year 2024 driven by a decline in our average outstanding borrowings and reductions in our interest rates. During December 2024, we drew on our revolving credit facility for share repurchases and working capital needs, which may result in higher interest expense charges in future quarters.
Provision for Income Taxes
Our effective income tax rate for the three months ended December 31, 2024, was 40.3%, compared to 25.0% for the three months ended December 31, 2023. The rate increase is a result of the disposition of our business in Australia and Korea, which negatively impacted the effective tax rate. For fiscal year 2025, we expect the effective tax rate on operations to be between 25.5% and 26.0%, with an overall effective tax rate of between 28.0% and 29.0%, including the results of the divestiture.
U.S. Federal Services Segment
Our U.S. Federal Services Segment delivers solutions that help various U.S. federal government agencies better deliver on their mission, including program operations and management, clinical services, and technology solutions. The segment also includes system and application development, IT modernization, and maintenance services. Clinical services comprises appeals and assessments services, which includes managing the evaluation process for U.S. veterans and service members on behalf of the VA and certain state-based assessments and appeals work that is part of the segment's heritage. Under TCS, the segment executes on its digital strategy to deliver technology solutions that advance agency missions, including the challenge to modernize, provide better customer experience, and drive process efficiencies.
Table MD&A 3: U.S. Federal Services Segment - Financial Results
(dollars in thousands)
| For the Three Months Ended December 31, 2024 | December 31, 2023 | |
|---|---|---|
| Revenue | $780,655 | $677,078 |
| Cost of revenue | 607,340 | 520,416 |
| Gross profit | 173,315 | 156,662 |
| Selling, general, and administrative expenses | 74,215 | 87,855 |
| Operating income | 99,100 | 68,807 |
| Gross profit percentage | 22.2 % | 23.1 % |
| Operating margin percentage | 12.7 % | 10.2 % |
Our revenue and cost of revenue for the three months ended December 31, 2024, increased 15.3% and 16.7%, respectively, compared to the three months ended December 31, 2023. All growth in the first quarter of fiscal year 2025 was organic.
Our revenue growth continues to be driven by clinical programs, including medical assessments, as well as broad growth across our portfolio of contracts. The first quarter of fiscal year 2025 received revenue and margin benefit from additional volume-based work, which is not expected to continue through the year.
We anticipate a full-year operating margin of approximately 11.5% for this segment in fiscal year 2025.
During the first quarter of fiscal year 2025, we received updates on two of our significant contracts.
- We have been re-awarded contracts to continue performing MDEs on behalf of the VA through 2026. A majority of the MDE contracts under the VA had ceilings on claims volumes at the time of award in 2018. Volumes significantly increased since the passage of the Honoring our PACT Act of 2022, thereby requiring a rebid process.
- The Centers for Medicare & Medicaid Services, which holds our Contact Center Operations contract, withdrew an early re-procurement of this arrangement which attempted to include a labor harmony agreement. We will continue work on this contract, which was awarded to us in 2022, and includes annual option periods through 2031.
U.S. Services Segment
Our U.S. Services Segment provides a variety of services, such as program operations, clinical services, employment services and technology solutions and related consulting work for U.S. state and local government programs. These services support a variety of programs, including the programs under the Affordable Care Act (ACA), Medicaid, the Children's Health Insurance Program (CHIP), Temporary Assistance to Needy Families (TANF), and child support programs. Program operations include comprehensive program administration services for government clients. The services we provide vary from program to program and include: centralized multilingual customer contact centers and multichannel, digital self-service options to better serve citizens' needs; application assistance to beneficiaries to help them access benefits; person centered clinical assessment services; provider enrollment systems and related business process services; employment services including eligibility support, case management, job-readiness preparation, job search and employer outreach, job retention and career advancement, and selected educational and training services. Our consulting services include technical and financial consulting services, including Independent Verification and Validation (IV&V) services, program modernization consulting; and project management.
Table MD&A 4: U.S. Services Segment - Financial Results
(dollars in thousands)
| For the Three Months Ended December 31, 2024 | December 31, 2023 | |
|---|---|---|
| Revenue | $452,250 | $489,845 |
| Cost of revenue | 357,246 | 371,482 |
| Gross profit | 95,004 | 118,363 |
| Selling, general, and administrative expenses | 54,158 | 52,300 |
| Operating income | 40,846 | 66,063 |
| Gross profit percentage | 21.0 % | 24.2 % |
| Operating margin percentage | 9.0 % | 13.5 % |
Our revenue and cost of revenue for the three months ended December 31, 2024, decreased 7.7% and 3.8%, respectively, compared to the three months ended December 31, 2023.
As noted at the time, our business in the first quarter of fiscal year 2024 was experiencing higher volumes from the resumption of Medicaid redetermination activities, driving benefits in both revenue and margins. Our business had returned to normal activity levels by the fourth quarter of fiscal year 2024.
We anticipate a full-year operating margin of approximately 11% for this segment in fiscal year 2025.
Outside the U.S. Segment
Our Outside the U.S. Segment provides BPS and technology solutions for international governments. These services include health and disability assessments, program administration for employment services, wellbeing solutions and other job seeker-related services, digitally-enabled customer services, and advanced technologies for modernization. We support programs and deliver services in various locations, including the United Kingdom, where we serve the newly awarded Functional Assessment Services (FAS) contract, which replaced the Health Assessment Advisory Service (HAAS) contract, and the Restart employment program. In recent years, we have divested components of the segment including, in the first quarter of fiscal year 2025, our businesses in Australia and Korea.
Table MD&A 5: Outside the U.S. Segment - Financial Results
(dollars in thousands)
| For the Three Months Ended December 31, 2024 | December 31, 2023 | |
|---|---|---|
| Revenue | $169,770 | $160,118 |
| Cost of revenue | 136,532 | 135,089 |
| Gross profit | 33,238 | 25,029 |
| Selling, general, and administrative expenses | 25,118 | 25,141 |
| Operating income/(loss) | 8,120 | (112) |
| Gross profit percentage | 19.6 % | 15.6 % |
| Operating margin percentage | 4.8 % | (0.1) % |
Table MD&A 6: Outside the U.S. Segment - Changes in Revenue, Cost of Revenue, and Gross Profit
(dollars in thousands)
| Revenue Amount | % Change | Cost of Revenue Amount | % Change | Gross Profit Amount | % Change | |
|---|---|---|---|---|---|---|
| Three months Ended December 31, 2023 | $160,118 | $135,089 | $25,029 | |||
| Organic effect | 17,106 | 10.7% | 9,468 | 7.0% | 7,638 | 30.5% |
| Disposal of businesses | (10,896) | (6.8)% | (10,866) | (8.0)% | (30) | (0.1)% |
| Currency effect compared to the prior period | 3,442 | 2.1% | 2,841 | 2.1% | 601 | 2.4% |
| Three months ended December 31, 2024 | $169,770 | 6.0% | $136,532 | 1.1% | $33,238 | 32.8% |
This segment has moved from breakeven to profitability between fiscal years 2024 and 2025.
We divested a number of employment services businesses over the past two years. The most significant divestiture impacting the results above is the sale of our operations in Australia and Korea in the first quarter of fiscal year 2025, which has reduced revenue and costs but provided a benefit to margin.
Organic growth was derived from our UK contracts, notably the FAS contract, as well as efficiency savings across the segment.
The currency benefit is principally from the British Pound, which was stronger in the first quarter of the current fiscal year.
We anticipate the full-year operating margin will range between 3% and 5% for this segment in fiscal year 2025.
Liquidity and Capital Resources
Our primary sources of liquidity are cash on hand, cash from operations, and availability under our revolving credit facilities. As of December 31, 2024, we had $72.7 million in cash and cash equivalents. We believe that our current cash position, access to our revolving debt, and cash flow generated from operations should be sufficient for our operating requirements for the next 12 months and beyond, including enabling us to fund required long-term debt repayments, dividends and any share purchases we might choose to make. See "Note 7. Debt and Derivatives" to the Consolidated Financial Statements for a more detailed discussion of our debt financing arrangements.
We have included the following table showing our debt balances as of December 31, 2024, and their effective interest rates.
Table MD&A 7: Debt Balances and Interest Rates as of December 31, 2024
(dollars in thousands)
| December 31, 2024 Carrying value | Effective cash interest rate | Interest rate basis | |
|---|---|---|---|
| Term Loan A - Hedged through May 2026 | $500,000 | 3.81% | Fixed rate of 2.31% plus margin. (1) |
| Term Loan A - Unhedged | 133,750 | 5.86% | Term SOFR reset monthly plus margin. (1) |
| Term Loan B - Hedged through September 2026 | 75,000 | 5.72% | Fixed Rate of 3.72% plus margin. (1) |
| Term Loan B - Hedged through September 2025 | 75,000 | 6.09% | Fixed Rate of 4.09% plus margin. (1) |
| Term Loan B - Unhedged | 347,500 | 6.36% | Term SOFR reset monthly plus margin. (1) |
| Revolver | 270,000 | 5.82% | Term SOFR reset monthly plus margin. (1) |
| Debt Principal | $1,401,250 |
(1) Applicable margins are currently 1.5% for the Term Loan A and Revolver and 2.0% for the Term Loan B. The Term Loan A and Revolver will vary based upon leverage starting in February 2025.
Our effective cash interest rate reflects the drivers of our cash interest payments as of December 31, 2024, which can change based upon the reset of the rates. Including the amortization of the upfront payments, our effective interest rate as of December 31, 2024, is 5.5%.
The below table summarizes our change in cash, cash equivalents, and restricted cash.
Table MD&A 8: Net Change in Cash and Cash Equivalents and Restricted Cash
(in thousands)
| Operating activities: | For the Three Months Ended December 31, 2024 | December 31, 2023 |
|---|---|---|
| Net cash (used in)/provided by operating activities | $(79,996) | $21,608 |
| Net cash used in investing activities | (22,256) | (20,432) |
| Net cash (used in)/provided by financing activities | (8,257) | 28,382 |
| Effect of foreign exchange rates on cash and cash equivalents and restricted cash | (2,384) | 1,846 |
| Net change in cash and cash equivalents and restricted cash | $(112,893) | $31,404 |
Net Cash (Used in)/Provided by Operating Activities
We reported an operating cash outflow for the first three months of fiscal year 2025, compared to cash from operations of $21.6 million in the first quarter of the 2024 fiscal year.
This outflow is consistent with slower receipts from our customers during the holiday period. Our Days Sales Outstanding ("DSO") at December 31, 2024, were 62 days, compared with 61 days at September 30, 2024.
In addition, the timing of income tax payments year-over-year has affected our operating cash flows, increasing outflows in the current fiscal year by approximately $13.0 million.
Net Cash Used in Investing Activities
We continue to make investments in our capital base, most notably in upgrading technology on our Federal MDE contracts. We anticipate the pace of this investment will decline through the latter half of fiscal year 2025.
Net Cash (Used in)/Provided by Financing Activities
We have utilized our revolving credit facility in fiscal year 2025 for working capital needs as well as purchases of Maximus common stock. During the first quarter of fiscal year 2025, we acquired 3.1 million common shares at a cost of $236.7 million. We also incurred charges from the recently-introduced excise tax on these purchases. Since December 31, 2024, we have acquired an additional 0.7 million common shares at a cost of $52.9 million, leaving approximately $85.0 million available for purchase under our existing program.
Credit Facilities
Our principal debt agreement is with JPMorgan Chase Bank N.A. (the "Credit Agreement"). At December 31, 2024, we owed $1.40 billion under the Credit Agreement, with access to an additional $480 million through a revolving credit facility. Our principal loans mature in May 2029 and May 2031, when the remaining balances must be renegotiated or repaid in full. The revolving facility also matures in May 2029. In addition, our term loans require quarterly mandatory repayments.
The Credit Agreement contains a number of covenants. Failure to meet these requirements would result in a need to renegotiate the agreement, seek a waiver, or a requirement to repay our outstanding debt in full. There are two financial covenants, both defined in the Credit Agreement:
- Our Consolidated Net Total Leverage Ratio means, for any twelve-month period, the ratio of our Funded Debt (as defined by the Credit Agreement), offset by up to $150 million of unrestricted cash (Consolidated Net Total Leverage), against our Consolidated EBITDA (as defined by the Credit Agreement). To comply with our Credit Agreement, this ratio cannot exceed 4.00:1.00 at the end of each quarter, with a step up to 4.50:1.00 under certain circumstances. This ratio also determines both our interest rate and the charge we pay on the unused component of our revolving credit facility, with the charge increasing as the leverage ratio increases.
- Our Consolidated Net Interest Coverage Ratio means, for any twelve-month period, the ratio of our Consolidated EBITDA against our Consolidated Net Interest Expense, as defined by the Credit Agreement. To comply with our Credit Agreement, this ratio cannot be less than 3.00:1.00 at the end of each quarter.
Consolidated EBITDA also drives certain permissions within the Credit Agreement, such as the level of investment we are entitled to make without seeking additional approval from our lenders.
Our Credit Agreement defines Consolidated EBITDA, as well as other components of the calculations above. The definition of Consolidated EBITDA requires us to include adjustments not typically included within EBITDA, including unusual, non-recurring expenses, certain non-cash adjustments, the pro forma effects of acquisitions and disposals, and estimated synergies from acquisitions. As a result, Consolidated EBITDA as defined by the Credit Agreement may not be comparable to EBITDA or related or similarly titled measures presented by other companies.
We have summarized below the components of our two financial ratio calculations, including the components of Consolidated EBITDA as defined by the Credit Agreement which are included within our financial statements. At December 31, 2024, we were in compliance with all applicable covenants of our Credit Agreement. We do not believe that these covenants represent a significant restriction on our ability to operate our business or to pay our dividends.
Table MD&A 9: Reconciliation of Net Income to Consolidated EBITDA as defined by our Credit Agreement
(in thousands)
| For the Three Months Ended December 31, 2024 | For the Trailing Twelve Months Ended December 31, 2024 | |
|---|---|---|
| Net income | $41,196 | $283,962 |
| Adjustments: | ||
| Interest expense | 17,522 | 78,455 |
| Other expense/(income), net | 312 | (625) |
| Provision for income taxes | 27,757 | 105,985 |
| Amortization of intangibles | 23,035 | 91,256 |
| Stock compensation expense | 6,952 | 32,874 |
| Acquisition-related expenses | 121 | 1,615 |
| Loss on sale of businesses | 38,341 | 38,341 |
| Depreciation and amortization of property, equipment, and capitalized software | 8,455 | 34,001 |
| Pro forma and other adjustments permitted by our Credit Agreement | 4,059 | 66,567 |
| Consolidated EBITDA (as defined by our Credit Agreement) | $167,750 | $732,431 |
28
(in thousands, except ratio data)
| Table MD&A 10: Consolidated Net Total Leverage Ratio | For the Trailing Twelve Months Ended December 31, 2024 |
|---|---|
| Funded Debt (as defined by our Credit Agreement) | $1,401,250 |
| Cash and cash equivalents up to $150 million | 72,653 |
| Consolidated Net Total Leverage (as defined by our Credit Agreement) | $1,328,597 |
| Consolidated Net Total Leverage Ratio (as defined by our Credit Agreement) | 1.81 |
(in thousands, except ratio data)
| Table MD&A 11: Consolidated Net Interest Coverage Ratio | For the Trailing Twelve Months Ended December 31, 2024 |
|---|---|
| Consolidated EBITDA (as defined by our Credit Agreement) | $732,431 |
| Interest expense | 78,455 |
| Components of other income/expense, net allowed in ratio calculation | 2,843 |
| Consolidated Net Interest Expense (as defined by our Credit Agreement) | $81,298 |
| Consolidated Net Interest Coverage Ratio (as defined by our Credit Agreement) | 9.01 |
Cash in Foreign Locations
We have no requirement to remit funds from our foreign locations to the United States. We will continue to explore opportunities to remit additional funds, taking into consideration the working capital requirements and relevant tax rules in each jurisdiction. When we are unable to remit funds back without incurring a penalty, we will consider these funds indefinitely reinvested until such time as these restrictions are changed. As a result, we do not record U.S. deferred income taxes on any funds held in foreign jurisdictions. We have not attempted to calculate our potential liability from any transfer of these funds, as any such transaction might include tax planning strategies that we have not fully explored. Accordingly, it is not possible to estimate the potential tax obligations if we were to remit all of our funds from foreign locations to the United States.
Free Cash Flow (Non-GAAP)
Table MD&A 12: Free Cash Flow (Non-GAAP)
(in thousands)
| For the Three Months Ended December 31, 2024 | December 31, 2023 | |
|---|---|---|
| Net cash (used in)/provided by in operating activities | $(79,996) | $21,608 |
| Purchases of property and equipment and capitalized software | (22,992) | (22,247) |
| Free cash flow (Non-GAAP) | $(102,988) | $(639) |
Critical Accounting Policies and Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires us to make estimates, judgments, and assumptions that affect the amounts reported. Actual results could differ from those estimates. The 2024 Form 10-K, as filed with the SEC on November 21, 2024, includes a summary of critical accounting policies we believe are the most important to aid in understanding our financial results. There have been no changes to those critical accounting policies that have had a material impact on our reported amounts of assets, liabilities, revenues, or expenses during the three months ended December 31, 2024.
Non-GAAP and Other Measures
We utilize non-GAAP measures where we believe it will assist users of our financial statements in understanding our business. The presentation of these measures is meant to complement, but not replace, other financial measures in this document. The presentation of non-GAAP numbers is not meant to be considered in isolation, nor as an alternative to revenue growth, net cash provided by operating activities, net income, or earnings per share as measures of performance or liquidity. These non-GAAP measures, as determined and presented by us, may not be comparable to related or similarly titled measures presented by other companies.
For the three months ended December 31, 2024, 12% of our revenue was generated outside the U.S. We believe that users of our financial statements wish to understand the performance of our foreign operations using a methodology that excludes the effect of year-over-year exchange rate fluctuations. To calculate year-over-year currency movement, we determine the current fiscal year's results for all foreign businesses using the exchange rates in the prior fiscal year.
In recent years, we made a number of acquisitions and divestitures. We believe users of our financial statements wish to evaluate the performance of our operations, excluding changes that have arisen due to businesses acquired or disposed of. We identify acquired revenue and cost of revenue by showing these results for periods for which no comparative results exist within our financial statements. We identify revenue and cost of revenue that has been disposed of in a similar manner. This information is supplemented by our calculations of organic growth. To calculate organic growth, we compare current fiscal year results, excluding transactions from acquisitions or disposals, to our prior fiscal year results.
Our previous acquisitions have resulted in significant intangible assets, which are amortized over their estimated useful lives. We believe users of our financial statements wish to understand the performance of the business by using a methodology that excludes the amortization of our intangible assets. For the three months ended December 31, 2024 and 2023, we also incurred losses on sales of businesses. We believe that providing supplemental measures that exclude the impact of the items detailed below is useful to investors in evaluating our core operations and results in relation to past periods. Adjusted EBITDA is also a useful measure of performance that focuses on the cash generating capacity of the business as it excludes the non-cash expenses of depreciation, amortization and divestiture-related charges, and makes for easier comparisons between the operating performance of companies with different capital structures by excluding interest expense and therefore, the impacts of financing costs. Accordingly, we have calculated our operating income, Adjusted EBITDA, net income, and diluted earnings per share, excluding the effect of the amortization of intangible assets and divestiture-related charges. As noted above, Adjusted EBITDA is calculated in a different manner from Consolidated EBITDA, as defined by our Credit Agreement. We have included a table showing our reconciliation of these income measures to their corresponding GAAP measures.
Table MD&A 13: Non-GAAP Adjusted Results - Operating Income, Adjusted EBITDA, Net Income, and Diluted Earnings per Share
(dollars in thousands, except per share data)
| For the Three Months Ended December 31, 2024 | December 31, 2023 | |
|---|---|---|
| Operating income | $86,787 | $107,510 |
| Add back: Amortization of intangible assets | 23,035 | 23,349 |
| Add back: Divestiture-related charges | 38,341 | 1,018 |
| Add back: Depreciation and amortization of property, equipment, and capitalized software | 8,455 | 8,411 |
| Adjusted EBITDA (Non-GAAP) | $156,618 | $140,288 |
| Adjusted EBITDA margin (Non-GAAP) | 11.2% | 10.6% |
| Net income | $41,196 | $64,148 |
| Add back: Amortization of intangible assets, net of tax | 16,977 | 17,208 |
| Add back: Divestiture-related charges | 38,341 | 1,018 |
| Adjusted net income excluding amortization of intangible assets and divestiture-related charges (Non-GAAP) | $96,514 | $82,374 |
| Diluted earnings per share | $0.69 | $1.04 |
| Add back: Effect of amortization of intangible assets on diluted earnings per share | 0.28 | 0.28 |
| Add back: Effect of divestiture-related charges on diluted earnings per share | 0.64 | 0.02 |
| Adjusted diluted earnings per share excluding amortization of intangible assets and divestiture-related charges (Non-GAAP) | $1.61 | $1.34 |
In order to sustain our cash flows from operations, we regularly refresh our fixed assets and technology. We believe that users of our financial statements wish to understand the cash flows that directly correspond with our operations and the investments we must make in those operations using a methodology that combines operating cash flows and capital expenditures. We provide free cash flow to complement our statement of cash flows. Free cash flow shows the effects of our operations and replacement capital expenditures and excludes the cash flow effects of acquisitions, purchases of our common stock, dividend payments, and other financing transactions. We have provided a reconciliation of cash flows from operations to free cash flow in "Liquidity and Capital Resources."
To sustain our operations, our principal source of financing comes from receiving payments from our customers. We believe that users of our financial statements wish to evaluate our efficiency in converting revenue into cash receipts. Accordingly, we provide DSO, which we calculate by dividing billed and unbilled receivable balances at the end of each quarter by revenue per day for the quarter. Revenue per day for a quarter is determined by dividing total revenue by 91 days.
Market risk
As filed, 517 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
In the normal course of business, we are exposed to financial risks such as changes in interest rates, foreign currency exchange rates, and counterparty risk. We use derivative instruments to manage selected interest rate exposures. The Company's market rate risk disclosures set forth in Part II, Item 7A, "Quantitative and Qualitative Disclosures About Market Risk" on the 2024 Form 10-K, as filed with the SEC on November 21, 2024, have not changed materially during the three month period ended December 31, 2024.
Controls and procedures
As filed, 1,541 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are effective and designed to ensure that the information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified by the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) identified in connection with the evaluation of our internal control that occurred during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 187 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There were no material changes during the three months ended December 31, 2024, to the risk factors previously disclosed in the 2024 Form 10-K, as filed with the SEC on November 21, 2024.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-10-01 to 2024-12-31 | $1.40bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2024-10-01 to 2024-12-31 | $1.10bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months2024-10-01 to 2024-12-31 | $301.6m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2024-10-01 to 2024-12-31 | $191.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-10-01 to 2024-12-31 | $86.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-10-01 to 2024-12-31 | $17.5m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2024-10-01 to 2024-12-31 | $27.8m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-10-01 to 2024-12-31 | $41.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-10-01 to 2024-12-31 | $0.69 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-10-01 to 2024-12-31 | $0.69 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-10-01 to 2024-12-31 | 60,002,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2024-10-01 to 2024-12-31 | −$80.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2024-10-01 to 2024-12-31 | $23.0m | us-gaap:PaymentsToAcquireProductiveAssets |
| Share repurchases | 3 months2024-10-01 to 2024-12-31 | $228.6m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2024-12-31 | $72.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-12-31 | $1.17bn | us-gaap:AssetsCurrent |
| Total assets | At period end2024-12-31 | $4.06bn | us-gaap:Assets |
| Current liabilities | At period end2024-12-31 | $678.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-12-31 | $2.41bn | us-gaap:Liabilities |
| Long-term debt | At period end2024-12-31 | $1.35bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2024-12-31 | $34.9m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2024-12-31 | $1.65bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001032220-25-000016. Last ingested by Listed: Oct 24, 2026, 15:04 ET. Listed shows no prices and gives no investment advice.